These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Carbapenem-Resistant Pseudomonas aeruginosa Infection and Mixed Infections Are Risk Factors for Poor Outcome After Lung Transplant. Wu Y; Zhu J; Huang L; Li M; Cui X; Zhan Q; Wang C Exp Clin Transplant; 2024 Apr; 22(4):300-306. PubMed ID: 38742321 [TBL] [Abstract][Full Text] [Related]
64. Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia. Bowers DR; Liew YX; Lye DC; Kwa AL; Hsu LY; Tam VH Antimicrob Agents Chemother; 2013 Mar; 57(3):1270-4. PubMed ID: 23263001 [TBL] [Abstract][Full Text] [Related]
65. Systemic inflammatory response syndrome in adult patients with nosocomial bloodstream infection due to Pseudomonas aeruginosa. Marra AR; Bar K; Bearman GM; Wenzel RP; Edmond MB J Infect; 2006 Jul; 53(1):30-5. PubMed ID: 16253333 [TBL] [Abstract][Full Text] [Related]
66. Treatment options and clinical outcomes for carbapenem-resistant Enterobacteriaceae bloodstream infection in a Chinese university hospital. Li C; Li Y; Zhao Z; Liu Q; Li B J Infect Public Health; 2019; 12(1):26-31. PubMed ID: 30145151 [TBL] [Abstract][Full Text] [Related]
67. Comparison of bloodstream and non-bloodstream infections caused by carbapenem-resistant Sun X; Zou X; Zhou B; Yin T; Wang P Front Med (Lausanne); 2023; 10():1230721. PubMed ID: 37795412 [TBL] [Abstract][Full Text] [Related]
68. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Lodise TP; Patel N; Kwa A; Graves J; Furuno JP; Graffunder E; Lomaestro B; McGregor JC Antimicrob Agents Chemother; 2007 Oct; 51(10):3510-5. PubMed ID: 17646415 [TBL] [Abstract][Full Text] [Related]
69. Prospective multi-center evaluation on risk factors, clinical characteristics and outcomes due to carbapenem resistance in Liu Y; Wang Q; Zhao C; Chen H; Li H; Wang H; Cares Network OBOT J Med Microbiol; 2020 Jul; 69(7):949-959. PubMed ID: 32584215 [No Abstract] [Full Text] [Related]
70. Risk Factors and Outcomes of Patients with Carbapenem-Resistant Wei X; Li L; Li M; Liang H; He Y; Li S Infect Drug Resist; 2023; 16():337-346. PubMed ID: 36698726 [TBL] [Abstract][Full Text] [Related]
71. Multi-drug resistant Pseudomonas aeruginosa and Acinetobacter baumannii infections among hospitalized patients: risk factors and outcomes. Shanthi M; Sekar U J Assoc Physicians India; 2009 Sep; 57():636, 638-40, 645. PubMed ID: 20214000 [TBL] [Abstract][Full Text] [Related]
72. Phenotypic characterization and colistin susceptibilities of carbapenem-resistant of Pseudomonas aeruginosa and Acinetobacter spp. Mohanty S; Maurya V; Gaind R; Deb M J Infect Dev Ctries; 2013 Nov; 7(11):880-7. PubMed ID: 24240048 [TBL] [Abstract][Full Text] [Related]
73. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Daikos GL; Petrikkos P; Psichogiou M; Kosmidis C; Vryonis E; Skoutelis A; Georgousi K; Tzouvelekis LS; Tassios PT; Bamia C; Petrikkos G Antimicrob Agents Chemother; 2009 May; 53(5):1868-73. PubMed ID: 19223638 [TBL] [Abstract][Full Text] [Related]
74. Acute Inflammatory Response of Patients with Pseudomonas aeruginosa Infections: A Prospective Study. Gómez-Zorrilla S; Morandeira F; Castro MJ; Tubau F; Periche E; Cañizares R; Dominguez MA; Ariza J; Peña C Microb Drug Resist; 2017 Jun; 23(4):523-530. PubMed ID: 27754817 [TBL] [Abstract][Full Text] [Related]
75. Carbapenem-sparing beta-lactam/beta-lactamase inhibitors versus carbapenems for bloodstream infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a systematic review and meta-analysis. Zhang H; Xu J; Xiao Q; Wang Y; Wang J; Zhu M; Cai Y Int J Infect Dis; 2023 Mar; 128():194-204. PubMed ID: 36621752 [TBL] [Abstract][Full Text] [Related]
76. Epidemiology, mortality and risk factors for patients with K. pneumoniae bloodstream infections: Clinical impact of carbapenem resistance in a tertiary university teaching hospital of Beijing. Zhang G; Zhang M; Sun F; Zhou J; Wang Y; Zhu D; Chen Z; Chen Q; Chang Q; Liu H; Chai W; Pan H J Infect Public Health; 2020 Nov; 13(11):1710-1714. PubMed ID: 33082112 [TBL] [Abstract][Full Text] [Related]
77. Risk factors and outcomes of inpatients with carbapenem-resistant Yuan Q; Guo L; Li B; Zhang S; Feng H; Zhang Y; Yu M; Hu H; Chen H; Yang Q; Qu T Front Microbiol; 2023; 14():1137811. PubMed ID: 37260693 [TBL] [Abstract][Full Text] [Related]
78. Risk Factors for Carbapenem-resistant Pseudomonas aeruginosa Infection in Children. Li L; Huang Y; Tang Q; Zheng Y Pediatr Infect Dis J; 2022 Aug; 41(8):642-647. PubMed ID: 35446814 [TBL] [Abstract][Full Text] [Related]
79. Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa. Pakyz AL; Oinonen M; Polk RE Antimicrob Agents Chemother; 2009 May; 53(5):1983-6. PubMed ID: 19273670 [TBL] [Abstract][Full Text] [Related]
80. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Tam VH; Gamez EA; Weston JS; Gerard LN; Larocco MT; Caeiro JP; Gentry LO; Garey KW Clin Infect Dis; 2008 Mar; 46(6):862-7. PubMed ID: 18279040 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]